FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2243670798> ?p ?o ?g. }

• W2243670798 abstract "16009 Background: According to prescribing information, pegfilgrastim should not be administered within 14 days prior to, or within 24 hours after, the administration of cytotoxic CT. However, little data exist to support this recommendation. The purpose of the current study is to determine the safety and efficacy of administering pegfilgrastim on the same day as myelosuppressive CT in patients with ovarian or primary peritoneal carcinoma. Methods: A retrospective review was conducted of all ovarian and primary peritoneal cancer patients that received prophylactic pegfilgrastim on the same day as CT from May 2003 to June 2006. Results: Forty-six patients (mean age: 57, range: 21–82) were treated for the following malignancies: 35 (76%) epithelial ovarian, 6 (13%) primary peritoneal, and 5 (11.0%) ovarian germ cell or stromal cell carcinoma. Twenty-six patients (56%) had primary cancers and 20 (44 %) had recurrent disease. All patients met the ASCO or NCCN recommendations of using colony-stimulating factors for prophylaxis against febrile neutropenia (FN) (Risk of FN > 20%). A total of 269 cycles of CT were administered including 125 cycles (46.5%) docetaxel + carboplatin, 39 cycles (14.5%) gemcitabine + platinum, 30 cycles (11.1%) intravenous paclitaxel + carboplatin, 28 cycles (10.4%) liposomal doxorubicin, 19 cycles (7.1%) paclitaxel + intraperitoneal platinum, 6 cycles (2.2%) docetaxel, 6 cycles (2.2%) liposomal doxorubicin + cisplatin, 5 cycles (2%) bleomycin + etoposide + cisplatin, 4 cycles (1.5%) topotecan, 3 cycles (1.1%) of paclitaxel, 2 cycles (0.7%) vincristine + actinomycin-D + cyclophosphamide, and 2 cycles (0.7%) docetaxel + gemcitabine. All patients received pegfilgrastim within one hour of the completion of CT administration. Grade 1 or 2 neutropenia developed in 10 cycles (3.7%) out of the 269 cycles, mean absolute neutrophil count = 4926 (range, 1293 -24300). No patients had FN episodes, hospitalizations or antibiotic use secondary to neutropenia, or dose-reductions and CT delays due to neutropenia. Conclusions: Administration of pegfilgrastim on the same day as CT in ovarian and primary peritoneal cancer patients is more convenient to the patient and appears safe and effective. No significant financial relationships to disclose." @default.
• W2243670798 created "2016-06-24" @default.
• W2243670798 creator A5002127671 @default.
• W2243670798 creator A5015151713 @default.
• W2243670798 creator A5023256468 @default.
• W2243670798 creator A5036412027 @default.
• W2243670798 creator A5038403332 @default.
• W2243670798 creator A5055177864 @default.
• W2243670798 creator A5055457903 @default.
• W2243670798 creator A5063914778 @default.
• W2243670798 creator A5067709805 @default.
• W2243670798 creator A5089545792 @default.
• W2243670798 date "2007-06-20" @default.
• W2243670798 modified "2023-09-23" @default.
• W2243670798 title "Safety and efficacy of pegfilgrastim administration on the same day as myelosuppressive chemotherapy (CT) in women with ovarian or primary peritoneal cancer" @default.
• W2243670798 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.16009" @default.
• W2243670798 hasPublicationYear "2007" @default.
• W2243670798 type Work @default.
• W2243670798 sameAs 2243670798 @default.
• W2243670798 citedByCount "0" @default.
• W2243670798 crossrefType "journal-article" @default.
• W2243670798 hasAuthorship W2243670798A5002127671 @default.
• W2243670798 hasAuthorship W2243670798A5015151713 @default.
• W2243670798 hasAuthorship W2243670798A5023256468 @default.
• W2243670798 hasAuthorship W2243670798A5036412027 @default.
• W2243670798 hasAuthorship W2243670798A5038403332 @default.
• W2243670798 hasAuthorship W2243670798A5055177864 @default.
• W2243670798 hasAuthorship W2243670798A5055457903 @default.
• W2243670798 hasAuthorship W2243670798A5063914778 @default.
• W2243670798 hasAuthorship W2243670798A5067709805 @default.
• W2243670798 hasAuthorship W2243670798A5089545792 @default.
• W2243670798 hasConcept C121608353 @default.
• W2243670798 hasConcept C126322002 @default.
• W2243670798 hasConcept C143998085 @default.
• W2243670798 hasConcept C2776694085 @default.
• W2243670798 hasConcept C2777063308 @default.
• W2243670798 hasConcept C2778658803 @default.
• W2243670798 hasConcept C2779171977 @default.
• W2243670798 hasConcept C2780427987 @default.
• W2243670798 hasConcept C71924100 @default.
• W2243670798 hasConceptScore W2243670798C121608353 @default.
• W2243670798 hasConceptScore W2243670798C126322002 @default.
• W2243670798 hasConceptScore W2243670798C143998085 @default.
• W2243670798 hasConceptScore W2243670798C2776694085 @default.
• W2243670798 hasConceptScore W2243670798C2777063308 @default.
• W2243670798 hasConceptScore W2243670798C2778658803 @default.
• W2243670798 hasConceptScore W2243670798C2779171977 @default.
• W2243670798 hasConceptScore W2243670798C2780427987 @default.
• W2243670798 hasConceptScore W2243670798C71924100 @default.
• W2243670798 hasLocation W22436707981 @default.
• W2243670798 hasOpenAccess W2243670798 @default.
• W2243670798 hasPrimaryLocation W22436707981 @default.
• W2243670798 hasRelatedWork W1973241390 @default.
• W2243670798 hasRelatedWork W1975491676 @default.
• W2243670798 hasRelatedWork W2095173560 @default.
• W2243670798 hasRelatedWork W2098455424 @default.
• W2243670798 hasRelatedWork W2417620129 @default.
• W2243670798 hasRelatedWork W2439707001 @default.
• W2243670798 hasRelatedWork W2443311901 @default.
• W2243670798 hasRelatedWork W2461409983 @default.
• W2243670798 hasRelatedWork W2471989939 @default.
• W2243670798 hasRelatedWork W2993175924 @default.
• W2243670798 isParatext "false" @default.
• W2243670798 isRetracted "false" @default.
• W2243670798 magId "2243670798" @default.
• W2243670798 workType "article" @default.